Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health President and CEO Jeffrey N. Simmons received a grant of 125.5855 deferred stock units on May 1, 2026. These units are tied to the company’s common stock at a reference price of $22.51 per unit and are part of his compensation, not an open-market trade. Following this award, his reported deferred stock unit balance is 24,164.1158 units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, settling after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.7526 deferred stock units, each tied to one share of common stock at a reference value of $22.51. After this compensation award, he holds 74.4993 deferred stock units in total.
The deferred stock units represent the right to receive either cash or Elanco common stock in the future. They generally settle after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan, rather than being an open-market stock purchase or sale.
Elanco Animal Health Inc is reported as having 26,138,990 shares beneficially owned by Vanguard Capital Management, representing 5.25% of the outstanding common stock as disclosed in a Schedule 13G. The filing states Vanguard Capital Management has sole dispositive power over all 26,138,990 shares and sole voting power over 3,802,866 shares.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 04/29/2026, and lists Vanguard affiliates and fund holdings as the basis for beneficial ownership. The report notes these holdings reflect securities managed on behalf of Vanguard funds and certain clients.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that President, CEO and Director Jeffrey N. Simmons received a grant of 119.3805 deferred stock units on April 17, 2026 at a reference price of $23.68 per unit. Following this award, he holds 24,038.5303 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after Simmons’ employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a small compensation-related award of deferred stock units. On this Form 4, he acquired 8.3201 deferred stock units tied to Elanco common stock, bringing his directly held deferred stock unit balance to 65.7467.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and will settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health officer Rajeev A. Modi received a grant of 62.3704 Deferred Stock Units. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent at a later time.
The units will settle in cash or shares following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan. After this award, Modi holds a total of 9,200.0091 Deferred Stock Units directly.
Elanco Animal Health Inc: Dimensional Fund Advisors filed an amended Schedule 13G/A reporting beneficial ownership of 24,527,135 shares of Elanco common stock, equal to 4.9% of the class. The filing shows sole voting power for 24,146,632 shares and was signed on 04/09/2026.
Elanco Animal Health is asking shareholders to elect five directors, ratify Ernst & Young as auditor, and approve an advisory vote on executive pay at its virtual 2026 annual meeting. The company highlights 2025 results of $4.715 billion revenue, $901 million adjusted EBITDA and $0.94 adjusted EPS, with 7% organic constant currency revenue growth and 10 consecutive quarters of underlying growth.
Innovation delivered $892 million of revenue in 2025, and Elanco targets about $1.15 billion of innovation revenue in 2026 plus 5–6 potential blockbuster approvals between 2026 and 2031. Net leverage was 3.6x in 2025, with a goal of less than 3x in 2027, supported by the Elanco Ascend productivity program, which is expected to provide $200–$250 million of adjusted EBITDA savings by 2030.
The proxy stresses governance changes, including a phased declassification of the Board by 2027, majority voting in uncontested director elections, proxy access, and shareholder rights to amend bylaws and call special meetings. Executive compensation remains heavily performance-based, with 2025 annual incentives paying at 109% of target and performance shares at 106% of target, and 2026 plans adding a relative total shareholder return metric and a sales growth modifier.
Elanco Animal Health Inc executive Rajeev A. Modi received a grant of deferred stock units as part of his compensation. On this award date, he acquired 64.7209 deferred stock units tied to Company common stock at a reference value of $22.82 per unit.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after his employment ends or in a specified future year under the Company’s Executive Deferral and Stock Match Plan. Following this grant, Modi holds a total of 9,137.6387 deferred stock units directly.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc President and CEO Jeffrey N. Simmons received a grant of 123.8795 deferred stock units on Company common stock. These units were valued at $22.82 per unit on the grant date and increase his directly held deferred stock unit balance to 23,919.1498 units.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. The units will settle in cash or shares following Simmons’ termination of employment or in a specified future year under the Company’s Executive Deferral and Stock Match Plan, making this a routine, compensation-related award rather than an open-market purchase.